Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II study of HTMC0435 tablets in combination with topotecan in extensive-stage small cell lung cancer and other solid tumors
CTR20222738Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0435 in small cell lung cancer (SCLC), Nonhematologic neoplasms, sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.. Started Feb 2023; status: active.
02
Drugs
HTMC0435
03
Conditions
small cell lung cancer (SCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222738.